Peptide data sheet
Mazdutide
GLP-1 · IBI362 · LY3305677
Verdict
promisingThe promising label reflects the published human trial data for weight and metabolic endpoints and a real regulatory approval in China; it is tempered by the fact that mazdutide is not FDA-approved in the United States, remains investigational there, and the research-grade material sold for lab use is not the reviewed pharmaceutical product.
Quick answer
Mazdutide (IBI362, LY3305677) is a peptide that acts on two metabolic receptors at once — the glucagon receptor and the GLP-1 receptor. It is most commonly researched for weight management and blood-sugar outcomes, and it has real human trial data behind it. China's regulator approved it for chronic weight management, but it is not FDA-approved in the United States; research-grade mazdutide sold for lab use is for laboratory research only.
- Class
- Dual agonist (glucagon / GLP-1 receptor)
- Half-life
- supports once-weekly research schedules (reported)
- FDA status
- Not FDA-approved in the United States. Mazdutide is approved by China's NMPA for chronic weight management but remains investigational in the U.S.; research-grade material sold for lab use is intended for laboratory research only.
- WADA banned?
- No
Which form actually works?
Injectable (subcutaneous)
Promising
The form used in the human trials and where essentially all of the research context lives. People report interest here because it matches how the compound was actually studied.
Oral
Unproven
Sometimes asked about by analogy to other metabolic drugs, but mazdutide's human data comes from the injectable form. An oral version is not where the studied evidence sits.